Ekaterina Valer'Evna Melnikova

Ekaterina Valer'Evna Melnikova

Auto-generated profile, based on publicly available information

Ekaterina Valer'Evna Melnikova

Scientific Centre for Expert Evaluation of Medicinal Products

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Citologiâ
Verified
Journal Article
Closed access
SFScientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation
Scientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation
EME.V. Melnikova
E.V. Melnikova
OMO.V. Merkulova
O.V. Merkulova
IBI.V. Borisevich
I.V. Borisevich
VMV.A. Merkulov
V.A. Merkulov
Разрабатываемые в настоящее время биомедицинские клеточные продукты (БМКП), а также продукты клеточных технологий, имеющих действующие бессрочно разрешения и лицензии на их использование, с 1 января 2017 г. регулируются Федеральным законом № 180-ФЗ от 23.06.2016 г. «О биомедицинских клеточных продуктах» и нормативно-правовыми актами, обеспечивающими его действие. Для некоторых медицинских технологий на сегодняшний день имеются положительные результаты практики клинического применения, однако правила производства, проведения доклинической оценки и клинических исследований таких препаратов до принятия № 180-ФЗ от 23.06.2016 г. не регулировались. Кроме того, для использования в практике здравоохранения БМКП должны пройти процедуру государственной регистрации. В обзоре представлены данные о типе препаратов на основе жизнеспособных клеток человека и опыте их применения до принятия № 180-ФЗ от 23.06.2016 г., а также о перспективных разработках, проводимых в Российской Федерации в области создания...

2 February 2023 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
ЕМЕ. В. Мельникова
Е. В. Мельникова
VMV. A. Merkulov
V. A. Merkulov
OMO. V. Merkulova
O. V. Merkulova
Neurodegenerative diseases (NDDs) are promising objects for the development of gene therapy products, primarily, due to the possible cause of these diseases (disruption of a gene or several genes), lack of effective therapy, and negative impact on the quality of life of both patients and their families and friends.The aim of the study was to identify trends and challenges in the development and preclinical and clinical studies of gene therapy products for NDDs and to analyse the international experience of expert assessment of the dossier for Zolgensma®, which received a conditional marketing authorisation.According to the analysis of the ongoing studies of gene therapy products for NDDs, the following major challenges arise at preclinical and clinical stages. For animal studies, a particular challenge is to select a disease model, a route of administration, and a target for effective gene therapy for polygenic disorders. For clinical trials, problematic aspects are the selection of a control group, the development of inclusion criteria for patients with a genetic variant that is an indication for a gene therapy product and exclusion criteria for patients with antibodies to this gene therapy product, the selection and justifi cation of a safe therapeutic dose since a gene therapy product can be administered to a patient only once, and the complexity of assessing clinical benefi ts of transgene expression in the human body due to the inaccessibility of brain tissue for analysis. Recent years have witnessed a breakthrough in gene therapy with the introduction of Zolgensma® (Novartis) to the world pharmaceutical market to treat children with spinal muscular atrophy type 1. The article analyses the experience of expert assessment of the marketing authorisation dossier for Zolgensma®, which can be used by drug developers bringing new medicines to the market of the Eurasian Economic Union under conditional marketing authorisation, which implies that the benefi ts of immediate patient access to these medicines will exceed the risks associated with incomplete data on their characteristics.

28 September 2018 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
ЕМЕ. В. Мельникова
Е. В. Мельникова
AGA. A. Goryaev
A. A. Goryaev
MSM. V. Savkina
M. V. Savkina
OMO. V. Merkulova
O. V. Merkulova
ACAlexander Chaplenko
Alexander Chaplenko
VMV. A. Merkulov
V. A. Merkulov
The intensive development of cellular technologies stipulates the introduction at the global level of medicinal products based on viable human cells, which in most countries are referred to as biomedical cell products. The authors conducted a comparative analysis of the regulatory framework in different countries and determined special aspects of regulation of cell therapy products (analogues of biomedical cell products). Some countries have mechanisms for priority review of cell therapy products for marketing authorization, such as accelerated assessment, accelerated approval, or conditional marketing authorisation. These mechanisms are currently absent in Russia, because of the novelty of the regulatory framework, and the biological properties of innovative cell products. Biomedical cell products are regarded as a separate class of medicinal products in Russia, they are not treated as biologicals and are regulated by the Federal Law No. 180-FZ «On Biomedical Cell Products» of June 23, 2016. The main difference in regulation of cell-based products in the Russian Federation is the principle of unified requirements for marketing authorisation of autologous, allogeneic, and combined biomedical cellular products, and the absence of the «hospital exemptions» mechanism that exists in many countries. This mechanism allows prescription and use of personalised autologous medicines produced in the laboratory of a medical institution for a particular patient.

25 March 2019 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
ЕМЕ. В. Мельникова
Е. В. Мельникова
ORO. A. Rachinskaya
O. A. Rachinskaya
GTGeorge Trusov
George Trusov
MKM. D. Khorolsky
M. D. Khorolsky
ISI. S. Semenova
I. S. Semenova
VMV. A. Merkulov
V. A. Merkulov
The manufacturer (developer) has to prepare a specification for each newly developed biomedical cell product (BCP) that has passed the stage of preclinical studies. The specification is included into the registration dossier when applying for marketing authorisation of a BCP. In accordance with the Order of the Ministry of Health of the Russian Federation No. 14n of 19 January 2017 «On approval of the specification format for a biomedical cell product» the specification should contain information about authenticity of the cell line used in the BCP, namely: morphological characteristics, expression of specific markers, expression of specific genes, expression of specific proteins, as well as markers of cell line stability. At present Russia has no practical experience in BCP quality evaluation. The aim of the study was to substantiate methodological approaches to authentication of cell lines used in BCPs as illustrated by quality evaluation of the DF-2 model cell line using test methods that allow for characterisation of the morphological, genetic, immunophenotypic, and cytogenetic profile of the cell line. Materials and methods: the study analysed the DF-2 cell line — human dermal fibroblasts (mesenchymal stem cells) obtained from the Institute of Cytology of the Russian Academy of Sciences (St. Petersburg). The following analytical test methods were used in the study: morphological analysis; flow cytometry for immunophenotyping of the DF-2 model cell line; short tandem repeats for creating an allelic profile of the model cell line; cytogenetic analysis — differential DAPI staining of metaphase chromosomes. Results: the paper summarises methodological approaches to identification testing of medicines containing living human cells (BCP analogues) currently used in international practice, and presents the results of authentication of the model cell line. Conclusions: methods used for BCP identification testing should ensure unambiguous authentication of the cell line according to its specification. The study performed helped to work out the procedure of authentication of a model cell line.

3 November 2024 in Regulatory Research and Medicine Evaluation
Verified
Journal Article
Open access
PDF file
MVM. A. Vodyakova
M. A. Vodyakova
НПН. С. Покровский
Н. С. Покровский
ISI. S. Semenova
I. S. Semenova
VMV. A. Merkulov
V. A. Merkulov
ЕМЕ. В. Мельникова
Е. В. Мельникова
INTRODUCTION. The degree of processing (manipulation) of cells included in a cell product and the functions performed after administration (homologous/non-homologous use) determine the classification of the cell product as a transplant or an advanced therapy medicinal product (ATMP) and, hence, the regulatory aspects of the product’s life cycle. Currently, the legislation of the Eurasian Economic Union (EAEU) and the Russian Federation does not sufficiently explain the terms ‘minimal manipulation’ and ‘homologous/non-homologous use’, which may lead to the use of cell products with unproven safety and efficacy in humans.AIM. This study aimed to compare Russian and international approaches to the interpretation of the terms ‘minimal manipulation’ and ‘homologous/non-homologous use’ for classifying cell products and determining their regulatory pathways, with stromal vascular fraction (SVF) products used as an example.DISCUSSION. This article reviews and summarises the regulatory approaches of the Russian Federation, the EAEU, the United States (US), and the European Union (EU) that are based on the classification of cell products according to the degree of cell manipulation and the functions performed after administration. The authors have analysed and compared the regulatory acts and approaches of the countries under consideration, with SVF products as a case study. The article highlights general aspects of interpreting the terms ‘minimal manipulation’ and ‘homologous/ non-homologous use’ and demonstrates the difference in regulatory approaches across several countries, which lies in the classification of enzymatic processing and selective collection of cells as substantial or minimal manipulation.CONCLUSIONS. The mechanism for regulating cell products depends on the degree of cell manipulation (substantial or minimal) and the intended use (homologous or non-homologous). A common principle adopted by regulatory agencies in the US, EU, EAEU, and Russia is to classify manipulation as minimal if the manipulated cells preserve their biological characteristics and physiological function. A defining characteristic of the homologous use of cells or tissues is their administration to perform their inherent functions in the body. In Russia, the regulatory acts for ATMPs and for transplants list the procedures classified as minimal manipulation. According to international standards, preparations based on minimally manipulated SVF cells are classified as ATMPs when used non-homologously. The lack of comprehensive and clear explanations of the terms ‘minimal manipulation’ and ‘homologous/non-homologous use’ in the legislation of the EAEU and the Russian Federation necessitates the development of relevant guidelines providing specific examples.

31 May 2021 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
ЕМЕ. В. Мельникова
Е. В. Мельникова
OMO. V. Merkulova
O. V. Merkulova
VMV. A. Merkulov
V. A. Merkulov
Current challenges to healthcare, i.e. the emergence of new diseases, lack of therapies for known diseases and life-threatening conditions, identification of patients who do not respond to standard treatment, on the one hand, and the evolution of scientific understanding of disease processes, medicines, therapies, causes of treatment failures, and implementation in clinical practice of innovations related to molecular biology and genetic engineering, on the other hand, create conditions and opportunities for the development of innovative medicinal products. A relatively new class of medicines is based on human cells and tissues (the term used in Russian legislation is biomedical cell products, BCP). However, the inability to accurately predict the efficacy and financial rewards of such medicines for pharmaceutical companies, as well as significant labour and financial costs associated with their development and clinical use, hinder their entry into the market. The aim of the study was to analyse the foreign regulatory setting for the development and launch of human cell- and tissue-based products, as well as approaches of foreign regulatory authorities to scientific advice, which can be drawn upon by the Russian expert authority when providing advice to BCP developers. The paper summarises the results of analysis of regulations establishing the procedure for providing scientific advice by EU, USA, and Russian regulatory authorities, and analyses the advice provided for the human cell- and tissue-based products which are now authorised in the EU and USA. The analysis of advice provided by foreign regulatory authorities shows that the largest number of consultations were given for medicinal products based on genetically modified cells for the treatment of cancer and genetic diseases. The questions were mainly related to the contents of specifications for finished pharmaceutical products, safety evaluation, curtailing of preclinical studies due to the lack of relevant animal/disease models, the number of subjects and efficacy endpoints in clinical studies, assessment of the appearance of replication-competent retroviruses.